Kit Gallagher
@kitcgallagher.bsky.social
Schmidt Science Fellow @ Massachusetts General Hospital | Harvard Medical School | Broad Institute (Vazquez-Garcia lab).
Developing quantitative tools to study cancer evolution through longitudinal and single cell genomics.
Developing quantitative tools to study cancer evolution through longitudinal and single cell genomics.
Reposted by Kit Gallagher
What does an Oxford mathematical biologist specialising in modelling cancer treatments do after completing their PhD? Why, go and do research at medical school, of course.
Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.
Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.
September 14, 2026 at 1:37 PM
What does an Oxford mathematical biologist specialising in modelling cancer treatments do after completing their PhD? Why, go and do research at medical school, of course.
Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.
Kit Gallagher, Schmidt Science Fellow at Harvard Medical School, is your man.
We present a new type of biomarker - based on a math equation rather than a genetic or transcriptomic assay.
By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.
By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.
In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics.
ja.ma/4wbDsyf
ja.ma/4wbDsyf
August 24, 2026 at 4:39 PM
We present a new type of biomarker - based on a math equation rather than a genetic or transcriptomic assay.
By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.
By capturing dynamic patterns in PSA during the first treatment cycle, we can predict prostate cancer outcomes across disease settings, paving the way for personalized treatment schedules.
I'm excited to be starting at a Schmidt Science Fellow - I'll be applying my maths background in genomics to characterize the role of chromosomal instabilities in cancer evolution.
Please reach out if you're interested in math modeling and quantitative tools for single-cell & longitudinal genomics!
Please reach out if you're interested in math modeling and quantitative tools for single-cell & longitudinal genomics!
We are thrilled to introduce our 2026 Schmidt Science Fellows — thirty-two incredible scientists set to embark on the next step of their interdisciplinary journey with our support. schmidtsciencefellows.org/news/the-202... @schmidtsciences.bsky.social
March 27, 2026 at 3:34 PM
I'm excited to be starting at a Schmidt Science Fellow - I'll be applying my maths background in genomics to characterize the role of chromosomal instabilities in cancer evolution.
Please reach out if you're interested in math modeling and quantitative tools for single-cell & longitudinal genomics!
Please reach out if you're interested in math modeling and quantitative tools for single-cell & longitudinal genomics!
Reposted by Kit Gallagher
Now time for @kitcgallagher.bsky.social on cool work with @mathonco.bsky.social on clinically applicable mathematical biomarkers using a Lotka-Volterra model #UKMathBio
September 4, 2025 at 11:09 AM
Now time for @kitcgallagher.bsky.social on cool work with @mathonco.bsky.social on clinically applicable mathematical biomarkers using a Lotka-Volterra model #UKMathBio
Chasing Perfection - previous work to optimize adaptive therapy schedules for cancer rely on monitoring the patient continuously. We find that accounting for discrete clinical appointments across multiple tumor models motivates patient-specific personalization in optimal tx!
doi.org/10.1101/2025...
doi.org/10.1101/2025...
Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics
Adaptive therapy (AT) protocols have been introduced to combat drug-resistance in cancer, and are characterized by breaks in maximum tolerated dose treatment (the current standard of care in most clin...
doi.org
April 9, 2025 at 6:16 PM
Chasing Perfection - previous work to optimize adaptive therapy schedules for cancer rely on monitoring the patient continuously. We find that accounting for discrete clinical appointments across multiple tumor models motivates patient-specific personalization in optimal tx!
doi.org/10.1101/2025...
doi.org/10.1101/2025...
Great news for the promotion and dissemination of open science, and hopefully institutions that benefit from this service will also be able to support this long-term initiative financially!
Big news: we are setting up a new non-profit organization to run bioRxiv and medRxiv. It's called openRxiv [no it's not a new preprint server; it's dedicated organization to oversee the servers] openrxiv.org 1/n
Homepage - openRxiv
openRxiv is an independent non-profit, the new organizational home for bioRxiv and medRxiv, enabling researchers to instantly share groundbreaking findings with the global scientific community.
openrxiv.org
March 12, 2025 at 12:53 AM
Great news for the promotion and dissemination of open science, and hopefully institutions that benefit from this service will also be able to support this long-term initiative financially!
#HiSciSky! I'm in the final year of my PhD applying math modeling and deep learning to improve treatment scheduling in late-stage cancers. I'm starting to look for #postdocs in #mathonco and cancer #evolution if you know anyone who's hiring!
January 6, 2025 at 5:47 PM
#HiSciSky! I'm in the final year of my PhD applying math modeling and deep learning to improve treatment scheduling in late-stage cancers. I'm starting to look for #postdocs in #mathonco and cancer #evolution if you know anyone who's hiring!
Reposted by Kit Gallagher
Sounds like what we need is something that makes it easier to generate quantitative, interpretable metrics that describe observable biological differences in tissue, without being a black box and requiring unreasonable amounts of training data...
www.muspan.co.uk
doi.org/10.1101/2024...
www.muspan.co.uk
doi.org/10.1101/2024...
December 13, 2024 at 12:58 PM
Sounds like what we need is something that makes it easier to generate quantitative, interpretable metrics that describe observable biological differences in tissue, without being a black box and requiring unreasonable amounts of training data...
www.muspan.co.uk
doi.org/10.1101/2024...
www.muspan.co.uk
doi.org/10.1101/2024...